News Daily

The Times

News from Asia

  • Written by Media Outreach
BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025. Zuellig Pharma holds the marketing authorization for Mounjaro® (tirzepatide) in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly and Company this year.

Mounjaro® (tirzepatide) is a once-weekly prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes; and as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

The availability of Mounjaro® (tirzepatide) is a significant advancement in the treatment of both obesity and type 2 diabetes, offering a single medication that can address both conditions through an easy-to-use prefilled pen. Mounjaro® KwikPen® (tirzepatide injection) is available in 2.5 mg, 5 mg, 7.5 mg and 10 mg, and gives healthcare providers the ability to personalize treatment plans better to meet individual patient needs.

Obesity is a critical public health concern in Thailand that affects 48% of the total population.2 The Ministry of Public Health classifies obesity as a Non-Communicable Disease (NCD) due to its strong link to rising rates for chronic illnesses, particularly type 2 diabetes. In 2024, the Department of Disease Control reported that 1 in 10 Thai individuals – a total of 6.5 million people – suffer from type 2 diabetes, impacting their physical, mental, and social well-being.2

People with diabetes face significant challenges in managing their blood sugar and preventing complications such as cardiovascular disease, chronic kidney disease, diabetic retinopathy, and diabetic foot ulcers, which can lead to severe infections and potential amputation.3

"Obesity and diabetes have gained prominence as significant health challenges in Thailand, and we are excited to accelerate the availability of Mounjaro® (tirzepatide) to patients in the region. With our deep understanding of the local regulatory landscape, as well as our proven track record of delivering innovative healthcare solutions in unmet disease areas, we are well placed to enhance the availability of the medicine in the market. This represents a significant step forward in our commitment to making healthcare more accessible, particularly in the chronic metabolic disease market," said Rehan Saghir, Executive Vice President of Zuellig Pharma's Commercialization division.

References:

  1. Mounjaro. Prescribing Information. Eli Lilly Asia, Inc.
  2. Division of Non-communicable Disease, Department of Disease Control, Ministry of Public Health)
  3. Yang, T., Qi, F., Guo, F. et al. An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory. Mol Med 30, 71 (2024). https://doi.org/10.1186/s10020-024-00824-9

Hashtag: #ZuelligPharma #EliLillyandCompany #Diabetes #Obesity #Healthcare #Pharmaceuticals

The issuer is solely responsible for the content of this announcement.

Read more

Why Compact Designs of Caravan Travel Transform Short Getaways

A caravan makes exploring Australia more flexible. For many Australians, a compact and practical setup makes short breaks easier, more comfortable and far more spontaneous. The layout inside significantly impacts how comfortable, organised and enjoyable your travels become.  Travellers often compare... Read more

7 Situations Where GPR Scanning Can Prevent Costly Construction Mistakes

Construction projects often rely on accurate information before excavation, drilling, coring or demolition begins. While plans, utility records and visual inspections provide valuable guidance, they don't always reveal what's hidden beneath the surface. Unknown utilities, reinforcement, voids or buried structures... Read more

Key Terms to Review Before Signing a Business Lease

A business lease can be a large financial commitment, and the terms buried in the fine print can affect your operation for years. It can be tempting to skim past the legal detail once you’ve found premises you like, but... Read more

When Should You Speak to Bankruptcy Lawyers About Debt Problems?

Debt problems rarely appear without warning, yet many people wait far longer than they should before seeking legal advice about their situation. By the time the decision is made to consult with bankruptcy lawyers, the available options are often more... Read more

Top Electrical Safety Tips from Inner West Sydney Electricians

While it may not be the most exciting subject to discuss, having an electrically safe home is definitely one of the most critical. Knowing the basics could help you avoid accidents and ensure your home remains in good condition, whether... Read more

When to Escalate a Debt Recovery Matter to Legal Action

Knowing when to transition from informal debt collection efforts to formal legal proceedings is a decision that many creditors find difficult to navigate. Acting too early can damage commercial relationships, while waiting too long can reduce the likelihood of recovery... Read more